Company

BioAge Labs

Source-reviewed Last reviewed: 2026-07-09

LN Evidence Score 3 of 5

LN Claim Risk Score 3 of 5

LN Commercial Maturity Score 2 of 5

LN Clinic Transparency Score 0 of 5

Source Summary

16 reviewed sources across 4 source categories.

Official company4
Investor relations / filing navigation7
Trial registry3
Independent context2

Jump to detailed source table

Company Snapshot

Company type Clinical-stage biopharmaceutical company

Identity and public positioning are based on reviewed official-company sources.

Public/private status Public company

Public-company context is included for source classification, not investment analysis.

Broad geography United States / global trial and public-company context

Geography is shown broadly based on the currently reviewed source set.

Platform focus Human aging biology and therapeutic program development

Company-described platform focus.

Longevity-relevant angle Aging-biology framing connected to pipeline and trial evidence posture

Tracks how aging-biology claims move into programs and trials; it does not establish longevity benefit.

Source posture Company-reported material with registry and independent context

Source categories are separated throughout the profile.

Last reviewed 2026-07-09

Source set and key company/trial facts reviewed on this date.

Confidence Editorial review complete; source freshness checked

Higher confidence for identity and registry facts; lower confidence for company-reported program and biomarker claims.

Executive Summary

BioAge Labs is a public clinical-stage biopharmaceutical company that describes a human-aging-biology platform and pipeline. LongevityNext treats BioAge as a company intelligence record because its public materials, trial registrations, and independent context illustrate how aging-biology claims move into programs and trials. This profile does not assess investment merit, product approval, efficacy, or individual use.

Why It Matters

BioAge is a useful signal for tracking how aging-biology framing appears in company strategy, program communications, trial registrations, and investor-facing materials. The important distinction is source posture: which claims are company-reported, which facts are registry-supported, and which conclusions still lack clinical outcome evidence.

Platform / Pipeline Overview

Program	Mechanism / pathway	Stage / status	Source type	Evidence boundary	Caution note
BGE-102 / NLRP3	NLRP3 inflammasome pathway	Company-reported Phase 1 data; QUELL-CV Phase 2 listed as recruiting	Company + trial registry	Supports program identity, company-reported biomarker context, and trial existence/status.	No efficacy, cardiovascular-outcome, or approval conclusion.
APJ program	APJ pathway	Company-reported / preclinical / lead-optimization background	Official company	Supports program and platform context.	Preclinical company-reported context; no clinical validation.
Azelaprag / STRIDES context	APJ-related program context with tirzepatide trial history	NCT06515418 terminated / Phase 2	Trial registry + independent context	Supports registry status and STRIDES history/discontinuation context.	No broader mechanism, safety, efficacy, or longevity conclusion.

Related Trials

Registry ID	Status / phase	Relationship	What it supports	What it does not prove
NCT07656727	Recruiting / Phase 2	External registry link for BioAge BGE-102 / QUELL-CV context	Trial existence, design/status, and sponsor/program context.	Efficacy, cardiovascular outcomes, approval, or treatment guidance.
NCT06515418	Terminated / Phase 2	External registry link for azelaprag / STRIDES context	Trial registration and status context.	Safety, efficacy, commercial future, or longevity benefit.
NCT06141889	Completed / Phase 1	External registry link for BGE-105 / azelaprag PK context	Registry-backed program-history context.	Clinical benefit, longevity effect, or consumer use.

Timeline / Milestones

2024 STRIDES Phase 2 trial entered the public registry record ClinicalTrials.gov / independent context
Establishes trial-history and discontinuation context.
2025 BioAge reported BGE-102 Phase 1 findings BioAge investor relations
Company-reported biomarker and safety observations.
2026 QUELL-CV Phase 2 listed in registry and company updates ClinicalTrials.gov / BioAge investor relations
Establishes program and recruiting-status context.
2026 Q1 pipeline update published BioAge investor relations
Company-reported program status.

Source Posture

Official company / investor relations

Company sources

Support identity, positioning, program descriptions, and reported milestones; they are not independent validation.

ClinicalTrials.gov

Trial registry

Supports trial existence, phase, design, and status facts; registration does not establish efficacy.

Investor-relations SEC index

Filing navigation

Provides access to public filing navigation; no investment conclusion is drawn.

Trade reporting

Independent context

Adds context for program events and discontinuation reporting; it is not clinical outcome evidence.

Reviewed source set

Source scope

This profile uses accessible official-company, investor-relations, trial-registry, filing-navigation, and independent-context sources. Claims requiring inaccessible or unverified material are excluded.

Evidence / Claim Boundary

Evidence boundary

Company-reported claims

Company materials describe programs and reported milestones; they are not independent validation.

Evidence boundary

Registry facts

Registry entries establish trial design and status facts; they do not establish efficacy.

Evidence boundary

Independent context

Independent reporting adds context but does not replace peer-reviewed or regulatory outcome evidence.

Evidence boundary

Scope of conclusion

The reviewed sources do not support a clinical-outcome or longevity-benefit conclusion.

What This Does Not Prove

Not established

Clinical outcomes or longevity benefit

The source set does not establish cardiovascular outcomes, disease prevention, patient-level utility, or human longevity benefit.

Not established

Approval or program success

Pipeline status and reported milestones do not establish safety, efficacy, approval, or future trial and commercial success.

Outside scope

Treatment, dosing, or investment guidance

This profile is not a treatment, dosing, consumer-use, investment, or valuation recommendation.

Detailed Sources

View detailed source table

Official company

Source	Type	Supports	Limitation	Link
BioAge main site	Official company	Company identity and broad public positioning.	Company-controlled source; not independent validation.	Open source
BioAge overview page	Official company	Company-described platform and business overview.	Company-controlled source.	Open source
BioAge NLRP3 / BGE-102 page	Official company	Program description and company-reported NLRP3 context.	Does not establish clinical outcome evidence.	Open source
BioAge APJ page	Official company	APJ program background and company-described context.	Company-reported/preclinical context; not clinical validation.	Open source

Investor relations / filing navigation

Source	Type	Supports	Limitation	Link
BioAge IR homepage	Investor relations	Company investor-relations source gateway.	Investor-relations source; not investment analysis.	Open source
BioAge press release index	Investor relations	Company press-release source navigation.	Company-controlled source; may be selective.	Open source
QUELL-CV first participant release	Investor relations	Company-reported BGE-102 / QUELL-CV milestone context.	Company-reported milestone; not efficacy evidence.	Open source
BGE-102 Phase 1 release	Investor relations	Company-reported Phase 1 biomarker/safety context.	Company-reported; not clinical outcome evidence.	Open source
BioAge Q1 2026 results release	Investor relations	Company update and pipeline context.	Company-reported; not investment analysis.	Open source
BioAge FY2025 results release	Investor relations	Company update and pipeline context.	Company-reported; not investment analysis.	Open source
BioAge IR SEC filings index	Filing navigation	Public-company filing navigation.	Navigation source only; no direct filing claim or investment analysis.	Open source

Trial registry

Source	Type	Supports	Limitation	Link
ClinicalTrials.gov NCT07656727	Trial registry	BGE-102 / QUELL-CV registry status and design context.	Trial registration does not imply efficacy or outcomes.	Open registry
ClinicalTrials.gov NCT06515418	Trial registry	Azelaprag / STRIDES registry status context.	Trial registration/status does not establish safety, efficacy, or future success.	Open registry
ClinicalTrials.gov NCT06141889	Trial registry	BGE-105 / azelaprag Phase 1 PK registry context.	Does not establish longevity or treatment benefit.	Open registry

Independent context

Source	Type	Supports	Limitation	Link
BioPharma Dive STRIDES context	Independent trade context	Independent context for azelaprag / STRIDES discontinuation reporting.	Context source, not clinical proof or investment analysis.	Open source
BioPharma Dive BGE-102 context	Independent trade context	Independent context for BGE-102/NLRP3 program reporting.	Context source, not clinical outcome evidence.	Open source

Confidence / Methodology

Editorial status

Confidence

Editorial review complete; source freshness checked

Scope

Methodology note

Company materials support identity, positioning, and reported milestones. Registry records support trial design and status facts. Independent reporting adds context. These sources do not establish clinical outcomes, longevity benefit, treatment or dosing guidance, or investment merit.

Freshness

Last reviewed

2026-07-09